MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/cas.70564

Медицинская библиотека · Cancer science · 2026

Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH-MM-15 Study.

Tsukamoto Taku, Shimura Yuji, Mizutani Shinsuke, Fujino Takahiro, Okamoto Haruya, Itagaki Mitsuhiro, Handa Hiroshi, Shimizu Takayuki, Sawamura Morio, Ishida Tadao, Kosugi Satoru, Ota Shuichi, Yoshimitsu Makoto, Shimazu Yutaka, Sugiura Isamu, Shibayama Hirohiko, Fuchida Shin-Ichi, Takamatsu Hiroyuki, Saito Akiko M, Kiyoi Hitoshi, Akashi Koichi, Matsumura Itaru, Takaori-Kondo Akifumi, Kuroda Junya, Iida Shinsuke

СтатьяПеревод пока не подготовлен

Аннотация

t(11;14) (q13;q32) occurs in approximately 15%-25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor. However, recent evidence suggests that MM with t(11;14) exhibits heterogeneous biological characteristics and clinical outcomes distinct from those associated with other cytogenetic risk categories. In a post hoc analysis of the prospective JSH-MM-15 study, we investigated the prognosis of newly diagnosed MM patients to identify prognostic features unique to t(11;14)-positive cases and to evaluate treatment factors influencing outcomes. Among 482 patients evaluated for t(11;14), 131 (27%) were positive. Overall survival (OS) in t(11;14)-positive patients was intermediate between standard- and high-risk groups, whereas progression-free survival (PFS) was comparable to that of high-risk cases. Deep response rates, including ≥ complete response (CR)/stringent CR and ≥ very good partial response, were lower in t(11;14)-positive MM than in other risk groups, and these responses were not associated with survival in t(11;14)-positive cases, in contrast to t(11;14)-negative MM. Compared with t(11;14)-negative MM, t(11;14)-positive patients more frequently expressed CD20 and less frequently expressed CD56 on myeloma cells. Exploratory analyses showed that, despite higher ≥ CR rates, OS was worse in patients with CD20-negative/CD56-negative tumors among t(11;14)-positive MM. Among CD20-positive patients, PI-containing regimens were associated with better OS, although no significant PFS benefit was observed. These findings support the biological and clinical heterogeneity of t(11;14)-positive MM and highlight the need for prospective validation of subgroup-specific treatment outcomes.

Для цитирования: Tsukamoto Taku, Shimura Yuji, Mizutani Shinsuke, Fujino Takahiro, Okamoto Haruya, Itagaki Mitsuhiro, Handa Hiroshi, Shimizu Takayuki, Sawamura Morio, Ishida Tadao, Kosugi Satoru, Ota Shuichi, Yoshimitsu Makoto, Shimazu Yutaka, Sugiura Isamu, Shibayama Hirohiko, Fuchida Shin-Ichi, Takamatsu Hiroyuki, Saito Akiko M, Kiyoi Hitoshi, Akashi Koichi, Matsumura Itaru, Takaori-Kondo Akifumi, Kuroda Junya, Iida Shinsuke. Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH-MM-15 Study.. Cancer science. 2026. DOI: 10.1111/cas.70564.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.